Boston Scientific Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -40

Boston Scientific (BSX) Faces Flat Watchman Revenue As Doctors Combine Heart Procedures - simplywall.st

AI-generated analysis

πŸ“‰ Watchman revenue is projected to be flat through Q3 2026 due to doctors combining the procedure with other heart surgeries instead of performing it standalone.

πŸ“Š The stock has fallen 56.2% over the last year and is down 21.1% in the past month, trading near $45.6.

⚠️ Brokers have cut price targets as analysts worry that reduced standalone volumes could weigh on confidence in hitting long-term revenue goals.

πŸ₯ The shift reflects a change in standard of care where physicians are rethinking procedure planning for left atrial appendage closure.

πŸ’Ό Boston Scientific maintains a diversified cardiovascular and MedSurg portfolio, including acquisitions like Axonics and Silk Road.

πŸ” Investors need to track if combined procedures become a lasting standard that stabilizes overall device utilization despite lower standalone numbers.

πŸ“‰ Peers such as Abbott and Medtronic are also facing pressure in the medical device sector, adding context to the broader industry environment.

πŸ’° Management faces decisions on whether to continue large-scale buybacks and acquisitions or prioritize balance sheet flexibility during this reset.

🎯 The narrative suggests that while Watchman growth is constrained, other parts of the portfolio may still support above-market procedure growth.

Bullish Signals
  • Boston Scientific possesses a diversified cardiovascular and MedSurg portfolio that analysts view as supportive even as Watchman expectations are reset.
  • The sharp decline in the stock price over the past year may create scope for sentiment to improve if execution stabilizes and constructive analyst narratives gain traction.
Risk Factors
  • Flat revenue expectations for the Watchman product line through Q3 2026 directly challenge previous growth assumptions tied to procedure volume.
  • A prolonged slowdown in Watchman procedures coupled with softer electrophysiology trends could keep overall company growth below investor expectations.
  • Repeated estimate cuts across Watchman and electrophysiology sectors may erode confidence in Boston Scientific's ability to hit longer-term revenue targets.
  • The stock has underperformed significantly, dropping 56.2% over the last year and 51.9% year-to-date, indicating sustained market skepticism.
Full Analysis
Boston Scientific's Watchman heart device revenue is expected to remain flat through Q3 2026 as physicians increasingly implant the device during combined cardiac procedures rather than as standalone treatments. This shift in clinical practice reduces standalone procedure volumes, altering the growth trajectory for this specific product line and requiring the company to adjust its strategic planning. The news arrives amidst significant pressure on Boston Scientific's stock, which has declined 56.2% over the past year and is trading around $45.6. The flat revenue outlook for Watchman coincides with several brokers cutting price targets, reflecting investor concerns that advanced cardiac procedures may not sustain previous growth rates without interruption. Analysts view this development as a key risk to Boston Scientific's ability to meet longer-term revenue targets, particularly given softer trends in electrophysiology. However, the company maintains a diversified portfolio including MedSurg and recent acquisitions like Axonics, which some analysts believe can provide support even as expectations for the Watchman line are reset. Investors are advised to monitor whether combined procedures stabilize overall device utilization and how management balances capital allocation between buybacks, acquisitions, and balance sheet flexibility. The situation highlights a broader industry challenge where peers like Abbott and Medtronic also face pressure in medical devices.